Sencer Göklemez

Elevated plasma anandamide levels in sclerotic chronic graft-versus-host disease highlight the endocannabinoid system as a potential therapeutic target

Sencer Göklemez, Steven Z. Pavletic, Hyoyoung Choo-Wosoba, Filip Pirsl et autres

us, at (code pays fourni par la source)

POSTER: MM-846: Treatment-Related Mortality and Predictors in Real-World Patients With Relapsed/Refractory Multiple Myeloma Treated With Teclistamab

Osama Younis, Sencer Göklemez, C Awadallah, Barry Paul et autres

jo, us (code pays fourni par la source)

MM-846: Treatment-Related Mortality and Predictors in Real-World Patients With Relapsed/Refractory Multiple Myeloma Treated With Teclistamab

Osama Younis, Sencer Göklemez, C Awadallah, Barry Paul et autres

jo, us (code pays fourni par la source)

Toward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force

Alina Markova, Stephanie J. Lee, Badri Modi, Emily Baumrin et autres

Peripheral Blood Stem Cell Collection for Patients with Multiple Myeloma Undergoing Autologous Transplant after Quadruplet Induction

Oren Pasvolsky, Denái R. Milton, Mark R. Tanner, Qaiser Bashir et autres

Prevalence of Atypical Chronic Graft-Versus-Host Disease Manifestations According to NIH Provisional Diagnostic Criteria

Sencer Göklemez, Kanak Parmar, Filip Pirsl, Steven Z. Pavletic et autres

us (code pays fourni par la source)

Exploring Novel Endocannabinoid Pathways in Sclerotic Chronic Graft-Versus-Host-Disease

Sencer Göklemez, Steven Z. Pavletic, Hyoyoung Choo‐Wosoba, Filip Pirsl et autres

us, at (code pays fourni par la source)

Toward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force

Alina Markova, Stephanie J. Lee, Badri Modi, Emily Baumrin et autres

The National Institutes of Health (NIH) chronic graft-versus-host disease (cGVHD) Consensus Project established response criteria that enabled clinical trials and facilitated regulatory approval of multiple therapies. Nonetheless, organ-specific assessments have limitations, particularly for severe sclerotic skin involvement. Cutaneous manifestations occur in approximately …

us, jp, ca, ch (code pays fourni par la source)

Cellular Therapy for Systemic Autoimmune Diseases: New Opportunities for Future Research and Interdisciplinary Collaboration

Elizabeth R. Volkmann, Sencer Göklemez, John Varga, Bruce R. Blazar et autres

Systemic autoimmune diseases (sAIDs) affect 1 in 10 people and represent a leading cause of death in women under the age of 65 years. Despite the emergence of targeted-biologic therapies, mortality rates for sAIDs have not improved. Emerging cellular therapies represent a …

us (code pays fourni par la source)

Prevalence of clonal hematopoiesis of indeterminate potential in patients with severe chronic graft-versus-host disease

Eduard Schulz, Filip Pirsl, Kathy McGraw, Darryl Nousome et autres

us (code pays fourni par la source)

Determinants and Clinical Significance of Musculoskeletal Symptoms in Patients With Chronic Graft-Versus-Host Disease

Ana Zelić, Filip Pirsl, Seth M. Steinberg, Sandra A. Mitchell et autres

Musculoskeletal symptoms in chronic graft-versus-host disease (cGVHD) are rare manifestations contributing to disease burden. This study assesses the frequency of muscle cramps, joint and muscle aches, and muscle weakness in a cohort of patients severely affected by cGVHD. Three hundred thirty-four patients …

us, hr (code pays fourni par la source)

Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus

Sencer Göklemez, Sarfaraz Hasni, Frances T. Hakim, Paolo A. Muraro et autres

OBJECTIVE: Autologous haematopoietic cell transplantation (AHSCT) improves immunologic dysfunction in patients with SLE. However, the curative potential of this therapy remains uncertain. This study reports outcomes in SLE patients receiving a lymphodepleting, reduced intensity regimen for AHSCT in SLE. METHODS: Eight patients …

in, us, gb (code pays fourni par la source)